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PPARα and Effects of TCE
We would like to offer a different opinion
on the ideas presented in the article by
Keshava and Caldwell (2006). The authors
indicated that their article summarized
scientific literature published since an earlier
U.S. Environmental Protection Agency
(EPA) risk assessment of trichloroethylene
(TCE), with an emphasis on the possible role
of proliferator-activated receptor α (PPARα)
agonism relevant to TCE risk assessment.
Interestingly, in the section on recent data on
PPARα agonism, Keshava and Caldwell
failed to establish any gene expression signa-
ture relating TCE and PPARα.
Keshava and Caldwell (2006) contended
that it is difficult to identify a clear pattern of
common gene expression changes for TCE
and PPARα agonists in general. However,
they did not consider numerous reports and
reviews (e.g., Klaunig et al. 2003; Peters et al.
2005) illustrating that there are common
and reproducible changes in gene expression
associated with PPARα agonists. Further,
extensive characterization has definitively
demonstrated specific, direct targets of
PPARα-retinoid X receptor heterodimers
(reviewed by Klaunig et al. 2003). Keshava
and Caldwell (2006) also did not discuss the
possibility that the effect of TCE on gene
expression could be mediated by mecha-
nisms independent of PPARα, which likely
explains the disparity described in their arti-
cle. Keshava and Caldwell did not critically
discuss the data summarized in their Table 2
(Keshava and Caldwell 2006), failing to note
that many of these gene targets have no clear
linkage with the PPARα agonist mode of
action (MOA) and may be mediated either
via different ligand–receptor–coactivator
complexes that form on the promoter
regions of the regulated genes by secondary
events downstream of the initial events asso-
ciated with PPARα activation, or by mecha-
nisms that are independent of PPARα. In
addition, the authors failed to describe the
limitations of the various gene array plat-
forms and to correctly interpret the findings
in the context of gene targets by other
PPARα agonists, especially when more com-
prehensive data sets exist but were not cited
(Anderson et al. 2004a, 2004b).
Keshava and Caldwell (2006) further
raised concerns regarding the use of PPARα-
null mice to evaluate the MOA of PPARα
by indicating that the physiologic differences
observed in PPARα-null mice relative to
wild-type mice suggest that the null mouse is
an inadequate model to study the PPARα
MOA. The data they cited, however, appears
selective because they failed to mention that
liver regeneration in PPARα-null mice is
reportedly unchanged compared with wild-
type mice (Rao et al. 2002), and age-related,
sexually dimorphic obesity has not been
observed in congenic PPARα-null mice
(Akiyama et al. 2001). Thus, although the
null mouse exhibits changes consistent with
the critical role of PPARα in modulating
fatty acid catabolism, this phenotype does
not preclude its application for determining
the critical role of this receptor in the MOA
of PPARα agonists. Importantly, Keshava
and Caldwell (2006) did not comprehen-
sively discuss significant findings a) that
PPARα-null mice are refractory to liver
tumors induced by two different PPARα
agonists (Hays et al. 2005; Peters et al.
1997); b) that they are refractory to increased
markers of replicative DNA synthesis and
suppression of apoptosis after exposure to
numerous PPARα ligands (summarized by
Peters et al. 2005); or c) that PPARα-null
mice expressing the human PPARα in the
liver respond to PPARα agonists by increas-
ing expression of genes encoding proteins
that catabolize lipids, but they fail to show
increases in markers of cell proliferation and
are resistant to liver cancer (Cheung et al.
2004; Morimura et al. 2006). To dismiss
these findings through lack of discussion or
citation does little to advance our under-
standing and suggests that Keshava and
Caldwell’s article is unbalanced.
Keshava and Caldwell (2006) also mis-
represented an earlier review by Klaunig et al.
(2003) regarding the MOA of PPARα ago-
nists. Keshava and Caldwell (2006) incor-
rectly suggested that Klaunig et al. (2003)
placed substantial weight on the associative
event of peroxisome proliferation with this
MOA, when, in fact, peroxisome prolifera-
tion was strongly—but not causally—associ-
ated, as noted for sustained increased cell
proliferation. Keshava and Caldwell (2006)
also misconstrued this review (Klaunig et al.
2003), focusing on DNA damage as a possi-
ble contributor to the MOA. Citing one
manuscript that examined the effect of one,
nonspecific PPARα ligand (DHEA) is not
sufficient to refute the comprehensive review
by Klaunig et al. (2003). Finally, Keshava and
Caldwell (2006) also suggested that the
effects of PPARα ligands on mitochondrial
function are part of the MOA, but they pro-
vided no direct evidence to support their con-
tention that PPARα agonists or TCE causes
mitochondrial dysfunction.
In summary, Keshava and Caldwell
(2006) missed an excellent opportunity to
critically and objectively examine the data
that support or refute the role of PPARα in
TCE-induced effects. In our opinion, their
article did not advance our understanding
of the MOA of PPARα agonists or TCE.
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PPARα and TCE: Keshava et al.
Respond
We appreciate the opportunity to discuss the
issues raised by Klaunig et al. in their letter.
First, we reiterate that, given the mini-mono-
graph’s scope (Chiu et al. 2006), our article
(Keshava and Caldwell 2006) was intended
not to comprehensively review the role of
peroxisome proliferator-activated receptor α
(PPARα) agonism in trichloroethylene
(TCE) toxicity but rather to “highlight some
of the recently published literature on
PPARα ... to help inform and illustrate the
key scientific issues relevant to TCE risk
assessment.” In addition, we considered not
just hepatocarcinogenesis, but a broader
range of modes of action (MOAs) and toxi-
city effects, necessitating a brief discussion
of the article by Klaunig et al. (2003).
Furthermore, because of the pending
National Academy of Sciences report and
revision of the TCE assessment, Klaunig
et al.’s suggestion to examine whether the
data “support or refute the role of PPARα
in TCE-induced effects” would have been
premature in the mini-monograph. 
In their letter, Klaunig et al. state that
there are “common and reproducible changes
in gene expression associated with PPARα
agonists.” However, as described by Klaunig
et al. (2003), the well-characterized changes
are largely peroxisomal or related to lipid
metabolism, and thus not causally related to
hepatocarcinogenesis. Hays et al. (2005) and
the Federal Insecticide, Fungicide, and
Rodenticide Act Science Advisory Panel
[FIFRA SAP (2004)] suggested that the
MOA underlying PPARα agonist-induced
hepatocarcinogenesis has not been fully eluci-
dated in that the specific target genes modu-
lated by PPARα leading ultimately to liver
cancer have not been identified. We share the
concerns of Klaunig et al. about critically
interpreting gene array data and the con-
cerns of Voss et al. (2006) about also consid-
ering dose-, time course–, species-, and
strain-related differences. Given reports that
PPARα agonists have zonal differences in
hepatocyte, peroxisomal, and mitochondrial
proliferation, and in foci development
(Anderson et al. 2004a; Bannasch 1996),
zone-dependent and nonparenchymal cell
responses (e.g., Kupffer cells) should also be
taken into account. Finally, Table 2 of our
article (Keshava and Caldwell 2006) illus-
trated the pleiotropic and varying liver
responses of the PPARα receptor to various
agonists, but we did not imply that these
responses were responsible for carcinogenesis.
We agree with Klaunig et al. that
PPARα-null mice have been useful in inves-
tigating the MOA for hepatocarcinogene-
sis, particularly for the strong agonist
WY-14,643 {[4-chloro-6-(2,3-xylidino)-2-
pyrimidinylthiol]acetic acid}. However, pos-
sible limitations of genetically modified
mice, such as lack of complete tumor devel-
opment or manipulation of the carcinogenic
process, should be adequately characterized
[U.S. Environmental Protection Agency)
(EPA) 2005]. Maronpot et al. (2004) noted
the need for lifetime studies to characterize
background or spontaneous tumor patterns
and life spans (including those of the back-
ground strain) for these models. 
PPARα-null mice have baseline differ-
ence from wild-type mice that may render
them more susceptible to toxic responses
[e.g., reduced glycogen stores, altered
responses to fasting, elevated plasma free
fatty acids, fatty liver, impaired gluconeo-
genesis, significant hepatic insulin resis-
tance (Lewitt et al. 2001)], or potentially
shorten their life spans with chemical expo-
sure (Anderson et al. 2004b; Hays et al.
2005) or with further genetic modification
(Nohammer et al. 2003). A comparison of
their life spans with those of background
strains without treatment has not been
reported. Moreover, in PPARα-null mice,
Wheeler et al. (2003) reported alteration of
cyclin-dependent kinase/cyclin complexes
necessary for cell cycle progression and
DNA synthesis, whereas Voss et al. (2006)
found increased apoptosis and decreased
mitosis with fumonisin treatment. Thus,
the question remains whether PPARα-null
mice may have different susceptibility to
hepatocarcinogenesis not specific to the
proposed PPARα MOA. 
Furthermore, bioassay study designs need
adequate sensitivity to detect carcinogenic
responses or elucidate MOAs. Morimura
et al. (2006) and Hays et al. (2005) used high
concentrations (with mortality), few (and dif-
fering numbers of) animals in treated versus
control groups, and differing periods of expo-
sure (all ≤ 1 year) complicating study inter-
pretation. Interestingly, in the “humanized”
PPARα-null mouse after 44 weeks of treat-
ment, Morimura et al. (2006) noted (along
with decreased toxicity) a WY-14,643–
induced adenoma resembling spontaneous
tumors rather than those seen in PPARα
agonist-treated wild-type mice; no tumors
were observed in controls. This raises the
question of whether, if tested for longer
periods of time, the humanized mice might
show significant responses with tumors
more consistent with those induced by a
variety of non-PPARα agonists and those
observed in humans (Bannasch 1996; Su
and Bannasch 2003).
We acknowledge the importance of
Peters et al. (1997) demonstrating in vivo
effects of WY-14,643 on replicative DNA
synthesis– and hepatocarcinogenesis–
involved PPARα activation. Furthermore, we
agree that peroxisome proliferation per se is
an associative rather than causal event in the
MOA for hepatocarcinogenesis (described by
Rusyn et al. 2000). However, Klaunig et al.
(2003) proposed a “minimal set of data ele-
ments” to support their PPARα MOA in
rodents that consists of “PPARα agonism
combined with light- or electron-micro-
scopic evidence of peroxisome proliferation”
or other markers of peroxisome proliferation.
In addition, Klaunig et al.’s claim that we
(Keshava and Caldwell 2006) misconstrued
their review (Klaunig et al. 2003) as focusing
on DNA damage as a possible contributor to
the MOA is incorrect; that hypothesis was
discussed by Reddy and Rao (1989). We
believe it is important to identify changes
both specific to PPARα activation and
related to carcinogenesis. 
Voss et al. (2006) reported fumonisin-
induced apoptosis, cell proliferation, gene
changes, and liver lesions to be PPARα-
independent but having some common tar-
get genes with PPARα agonists. Thus, we
should not only understand a particular
agent’s effects on the cell cycle and prolifera-
tion but also establish dependence on
PPARα. Another issue is the applicability of
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Hays et al. (2005) noted that much of the
literature on the PPARα MOA used
WY-14,643, which induces sustained cell
proliferation, whereas weaker agonists pro-
duce more transient responses (Marsman
et al. 1988). Kraupp-Grasl et al. (1990)
noted differences among agonists in their
abilities to promote tumors and suggested
that they should not necessarily be consid-
ered a uniform group. Finally, the discus-
sion of the effects of PPARα agonists on
mitochondrial function in our article
(Keshava and Caldwell 2006) was intended
to raise the issue for further investigation.
Similar issues with respect to PPARα
have been discussed by recent scientific
panels (FIFRA SAP 2004; U.S. EPA
Science Advisory Board 2006). We believe
that our article (Keshava and Caldwell
2006), Klaunig et al.’s letter, and this
response help to further elucidate these
complex issues for the assessment of TCE as
well as other chemicals. 
The views expressed in this article are those
of the authors and do not necessarily reflect the
views or policies of the U.S. EPA.
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Aspartame Not Linked to
Cancer
In an article published in the March 2006
issue of Environmental Health Perspectives
(EHP) Soffritti et al. (2006) of the European
Ramazzini Foundation of Oncology and
Environmental Sciences (ERF) reported that
aspartame was associated with an increase in
lymphomas and leukemias, transitional cell
carcinomas of the renal pelvis and urether,
malignant schwanomas of peripheral nerves,
and hyperplasia of the olfactory epithelium. 
After the publication of the ERF aspar-
tame study (Soffritti et al. 2006), the
European Commission asked the European
Food Safety Authority (EFSA) to assess the
ERF aspartame carcinogenicity study
results as a matter of high priority follow-
ing the publication (EFSA 2005). The
EFSA’s Scientific Panel on Food Additives,
Flavorings, Processing Aids and Materials in
Contact with Food (AFC), an 18-member
panel that consisted of independent regula-
tory scientists and toxicologists, assessed the
ERF aspartame carcinogenicity study using
not only the ERF publication but also more
extensive primary data and reports provided
by ERF (EFSA 2006). Concurrently, the
U.K. Food Standards Agency requested
the opinion of the U.K. Committee on
Carcinogenicity of Chemicals in Food,
Consumer Products and Environment
(COC) on the quality, analysis, and interpre-
tation of the results of the ERF aspartame
carcinogenicity study (Soffritti et al. 2006). 
After a lengthy evaluation process, on
5 May 2006, the EFSA published a 44-page
report (EFSA 2006). A summary comment
of the EFSA report on ERF study included
the following: 
The increased incidence of lymphomas/leukaemias
reported in treated rats was unrelated to aspartame,
given the high background incidence of chronic
inflammatory changes in the lungs and the lack of
a positive dose–response relationship. … The
slight increase in incidence of these tumours in rats
fed aspartame is considered to be an incidental
finding of the ERF study and can therefore be dis-
missed. (EFSA 2006)
The preneoplastic and neoplastic lesions of the
renal pelvis, ureter and bladder occurring primarily
in female rats along with renal calcification were
most probably treatment-related, at least at the
higher doses. It is widely accepted that the effect is
a high dose effect of irritant chemicals or chemicals
producing renal pelvic calcification as a result of
imbalances in calcium metabolism, specific to the
rat. The Panel considers that these effects are of no
relevance for humans. (EFSA 2006)
The data on total malignant tumours do not pro-
vide evidence of a carcinogenic potential of aspar-
tame. … [T]he aggregation of all malignant
tumour incidences or all malignant tumour-bear-
ing animals for statistical purposes is not justified,
given that, as explained above, the lymphomas/
leukaemias and the renal tumours should have
been excluded from the analysis. (EFSA 2006)
Concerning the malignant schwannomas, … the
numbers of tumours were low, the dose–response
relationship, while showing a positive statistical
trend in males, was very flat over a wide dose
range and there is also uncertainty about the diag-
nosis of these tumours. … [T]his finding can only
be fully evaluated following a histopathological
peer-review of all relevant slides related to the ner-
vous system in the ERF study and if necessary also
from the historical controls. (EFSA 2006)
Furthermore, the COC’s March 2006
minutes on the publication of the ERF aspar-
tame study (Soffritti et al. 2006) concluded, 
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study and some concerns about the microbiologi-
cal status of the colony, it was not possible to
draw conclusions about the potential carcino-
genicity of aspartame from the results.
The study by Soffritti et al. (2006) has
major flaws that bring into question the
validity of the findings. Its publication in
EHP is not without consequence to the
reputation of the National Institute of
Environmental Health Sciences or to the
health of the U.S. public. Publication of
invalid and misleading research results relat-
ing to products such as aspartame, which can
be of benefit in the battle against obesity and
have a history of safe use, are a disservice to
the tax-paying citizens of the United States. 
The author is employed by Ajinomoto USA,
which sells aspartame.
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Aspartame: Soffritti Responds 
As communicated in his letter, Abegaz repre-
sents Ajinomoto Corporate Services LLC.
Ajinomoto, which holds 45% of the market
share for worldwide aspartame production
(Ajinomoto 2006), is well known for its
aggressive and effective defense of its com-
mercial interests. The action by Abegaz to
reproduce portions of the opinion issued by
the European Food Safety Authority (2006)
regarding the results of our long-term car-
cinogenesis bioassay on aspartame (Soffritti
et al. 2006) is clearly specious. 
The author declares he has no competing
financial interests.
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Children’s Health/Regional
Collaboration to Reduce Lead
Exposure in Children
As Safi et al. (2006) discussed, environ-
mental contamination does not stop at inter-
national boundaries. An excellent example of
a collaborative effort to address regional envi-
ronmental exposures is that of the public
health communities in Israel, Jordan, and the
Palestinian Authority to assess and limit lead
exposure of young children. Their dedication
to this project in the face of significant politi-
cal upheavals and episodic violence has
demonstrated a remarkable commitment
among international public health colleagues
to improve environmental public health. 
Safi et al. (2006) underscored the three
most important strategies to prevent lead
exposure in young children. First, eliminate
leaded gasoline. In countries where this strat-
egy has been successfully implemented, blood
lead levels have significantly decreased (Pirkle
et al. 1994; Schnass et al. 2004). More than
50 nations have eliminated lead in gasoline,
and many others will initiate phase-outs over
the next few years (Landrigan 2002). 
Second, identify other consequential
sources of lead and take action to control or
eliminate them. Smelting remains a preva-
lent hazard in many parts of the world
(ATSDR 1999). Efforts such as recycling
batteries in controlled facilities have been
successful in some countries. 
Third, expand surveillance to ensure that
recurrent or new sources of lead exposure are
identified and that appropriate actions are
taken. Both children and exposure sources
travel. In the United States, we have found
that the risk of lead exposure is much higher
among immigrants when they arrive in the
United States, usually as a result of use of
lead-containing products; this elevated risk
for exposure continues after immigrants relo-
cate when the children are exposed to lead in
paint and house dust (CDC 2005). 
This collaborative project in the Middle
East is an outstanding model for other inter-
national efforts to control environmental
contaminants in complex regional settings.
Safi et al. (2006) have shown tremendous
vision, integrity, and commitment to public
health under very difficult circumstances.
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Editor’s note: In accordance with journal
policy, Safi et al. were asked whether they
wanted to respond to this letter, but they chose
not to do so.
Flawed Ethics Recommendations
of the U.S. EPA’s Human Studies
Review Board 
The U.S. Environmental Protection Agency’s
(EPA) new rule to protect human research
subjects has generated scientific, ethical, and
legal controversy (Burton 2006). Addressing
pesticide studies submitted by third parties
to the U.S. EPA for possible use in regula-
tory decisions, the rule also authorized an
independent Human Subjects Review Board
(HSRB) to evaluate these studies. How suc-
cessful has the HSRB been? 
The board’s first report (HSRB 2006), a
scientific and ethical review of third-party,
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eight active ingredients used in pesticides,
was issued 26 June 2006. The HSRB
(2006) concluded that studies of seven pes-
ticides [aldicarb, amitraz, azinphos-methyl,
dichlorvos (DDVP), ethephon, methomyl,
and oxamyl] “failed to fully meet the spe-
cific ethical standards prevalent at the time
the research was conducted …” (see also
Lockwood 2004; Needleman et al. 2005;
Oleskey et al. 2004; Sass and Needleman
2004). Nevertheless, the HSRB (2006)
concluded that 
There was no clear and convincing evidence that
the research [on these seven pesticides] was fun-
damentally unethical—intended to seriously
harm participants or that informed consent was
not obtained.
This second HSRB conclusion is ethi-
cally questionable on several grounds. First,
it relies on an arbitrary definition of “funda-
mentally unethical” research as either
intended to seriously harm participants or
that fails to obtain informed consent. Yet
neither the U.S. EPA (2006) nor the
National Research Council (NRC 2004)
defines “fundamentally unethical” so nar-
rowly. Instead, both say only that studies
which intend harm or violate consent are
examples of “fundamentally unethical”
research. 
research to only two types of problems, the
HSRB excludes much behavior that ethicists
traditionally have condemned. Negligence
and culpable ignorance (Aristotle 1985)—as
well as lying, using people as means to an
end, or pursuing self-interest at the expense
of others (Kant 1964)—are unethical, even
without intent to harm others. 
To assume that bad intentions are
required to make serious harms fundamen-
tally unethical also ignores “errors of omis-
sion” and focuses merely on commission—
having harmful intent. Yet researchers err
through omission if they behave irresponsibly
toward their subjects: Perhaps they intend no
harm, but through laziness, greed, or careless-
ness (Aristotle 1985), they fail to recognize
subjects’ manifesting harmful symptoms.
The second HSRB conclusion also
imposes an unfair burden on research victims
or opponents, requiring them to establish
researchers’ intentions. Yet intentions are
almost impossible to know; they are pri-
vate—not empirical—and thus typically
known only by the individual. Proof of intent
to harm is not required to judge bank robbers
or white-collar criminals. Why should evalua-
tors of research have such an unfair burden? 
One reason for the HSRB’s questionable
ethical conclusions may be inadequate
bioethics expertise. No board members have
terminal degrees in bioethics or even ethics.
Fields represented are anesthesiology, envi-
ronmental health sciences (2), epidemiology,
medicine, microbiology, neurology, pharma-
cology (3), psychology, statistics (2), and
toxicology (3) (HSRB 2006). The U.S. EPA
also has not followed recommendtions of its
Science Advisory Board (2000), the NRC
(2004), and the Environmental Medicine
Workgroup (Oleskey et al. 2004) to establish
specific ethics guidelines for all U.S. EPA-
related research. Without such guidelines
(e.g., avoid low-power studies), questionable
ethical conclusions likely will continue. 
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